(Q34761321)

4 August 2017

1 reference

title

Neuroendocrine pathobiology of chronic critical illness (English)

1 reference

4 August 2017

1

Greet Van den Berghe

0 references

publication date

1 July 2002

1 reference

4 August 2017

published in

Critical Care Clinics

1 reference

4 August 2017

volume

18

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

509-528

1 reference

Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Protein metabolism and the use of growth hormone and insulin-like growth factor-I in the critically ill patient

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

A Paradoxical Gender Dissociation within the Growth Hormone/Insulin-Like Growth Factor I Axis during Protracted Critical Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

APACHE II: a severity of disease classification system

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

A receptor in pituitary and hypothalamus that functions in growth hormone release

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Measurement of Human Growth Hormone Receptor Messenger Ribonucleic Acid by a Quantitative Polymerase Chain Reaction-Based Assay: Demonstration of Reduced Expression after Elective Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after caecal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2 and -3 mRNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Acquired growth hormone resistance in patients with hypercatabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Growth hormone and insulin-like growth factors in critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Growth hormone secretion in critical illness: effect of dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Anterior pituitary function during critical illness and dopamine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Lack of nocturnal serum thyrotropin surge after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Decreased nocturnal surge of thyrotropin in nonthyroidal illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Prediction of outcome in intensive care patients using endocrine parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Effect of Tri-Iodothyronine Replacement on the Metabolic and Pituitary Responses to Starvation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Thyroid hormone treatment after coronary-artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

The relationship between serum triiodothyronine and thyrotropin during systemic illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Dopamine and the sick euthyroid syndrome in critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Reduced tissue thyroid hormone levels in fatal illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Alterations of mental status and thyroid hormones after thermal injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Hypermetabolic low triiodothyronine syndrome of burn injury

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Circulating immunoreactive inhibin and testosterone levels in men with critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Effect of surgical stress on pituitary-testicular function

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Effect of acute myocardial infarction on pituitary-testicular function.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Human Prolactin and Growth Hormone Release during Surgery and other Conditions of Stress1

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Reproductive function during fasting in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Pituitary-testicular axis dysfunction in burned men.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Effect of burn trauma on adrenal and testicular steroid hormone production

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Suppression of plasma testosterone levels and psychological stress. A longitudinal study of young men in Officer Candidate School

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Transient hypogonadotropic hypogonadism caused by critical illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Function of the Male Sex Organs in Heroin and Methadone Users

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Physiological Functions of Glucocorticoids in Stress and Their Relation to Pharmacological Actions*

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Evidence for adrenocortical adaptation to severe illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Dehydroepiandrosterone sulphate in critical illness: effect of dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Hyperreninemic Hypoaldosteronism in the Critically 111: A New Entity*

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Adrenal insufficiency in the surgical intensive care unit patient

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Novel insights into the neuroendocrinology of critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Inhibitors of glucose uptake stimulate the production of insulin-like growth factor-binding protein (IGFBP-1) by human fetal liver

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Circulating binding proteins for the insulinlike growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Intensive insulin therapy in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

Increased mortality associated with growth hormone treatment in critically ill adults

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900007-6

7 January 2021

10.1016/S0749-0704(02)00007-6

Identifiers

DOI

1 reference

4 August 2017

1 reference